Toggle Main Menu Toggle Search

Open Access padlockePrints

Biologic Frameworks for Synucleinopathies: Contributions of the Parkinson's Progression Markers Initiative

Lookup NU author(s): Professor Nicola PaveseORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

© 2026 American Neurological Association.A research biologic definition and staging of neuronal alpha-synucleinopathies, including Parkinson's disease and dementia with Lewy bodies, is critical toward improving clinical trial design and drug development. Neuronal synuclein disease, and the companion Integrated Staging System, are a biologic definition and staging system conceptualized by multiple stakeholders including academia, industry, advocacy organizations, and importantly, people with lived experiences. In large part, this was informed and enabled by the knowledge garnered from the Parkinson's Progression Markers Initiative. This review provides a historical perspective and details contributions from the Parkinson's Progression Markers Initiative, among others, that made this advancement possible. These include the key role it played in validation of an in vivo biomarker of neuronal alpha-synuclein, longitudinal characterization of dopaminergic dysfunction imaging, biospecimen collection and assays, comprehensive genetic characterization, and clinical phenotyping. In addition, the Parkinson's Progression Markers Initiative is generating and sharing data that will be used to address key gaps in knowledge, revisions, and future refinements of a biologic definition and staging of synucleinopathies. ANN NEUROL 2026.


Publication metadata

Author(s): Chahine LM, Alcalay RN, Brown EG, Chowdhury S, Coffey CS, Foroud T, Frasier M, Galasko D, Merchant KM, Mollenhauer B, Tolosa E, Pavese N, Tropea TF, Marek K, Simuni T

Publication type: Editorial

Publication status: Published

Journal: Annals of Neurology

Year: 2026

Pages: Epub ahead of print

Online publication date: 06/05/2026

Acceptance date: 21/04/2026

ISSN (print): 0364-5134

ISSN (electronic): 1531-8249

Publisher: John Wiley and Sons Inc

URL: https://doi.org/10.1002/ana.78249

DOI: 10.1002/ana.78249

PubMed id: 42089472


Share